Joint venture · MENA · Announced 8 Nov 2024
Shanghai Henlius Biotech → SaudiVax
Joint venture deal between Shanghai Henlius Biotech (China) and SaudiVax (Saudi Arabia), covering adalimumab, announced 8 Nov 2024. Value: Undisclosed.
Parties: Shanghai Henlius Biotech (Fosun Pharma group) (China) → SaudiVax (Saudi Arabia)
- Deal type
- Joint venture
- Value
- Undisclosed
- Territory
- MENAT (Middle East, North Africa, Türkiye); Saudi Arabia as manufacturing & operational base
- Therapeutic area
- Oncology
- Asset
- adalimumab (HANDAYUAN / HLX03), bevacizumab (HANBEITAI / HLX04)
- Announced
- 8 Nov 2024
Our analysis
Why this matters
It's a JV to make biologics locally, not just sell them. Unlike a standard licensing-and-supply deal, Henlius and SVAX are establishing joint ventures for manufacturing as well as commercialization inside Saudi Arabia — pairing Henlius's biologics-development and supply capability with SVAX's local regulatory, manufacturing and commercial infrastructure.
The lead assets are two high-value biosimilars: adalimumab (reference Humira — the world's historically best-selling drug, immunology/inflammation) and bevacizumab (reference Avastin — oncology).
The full analysis is free to read with a work email on this page.
Source: PR Newswire / Henlius